コンテンツにジャンプ
先端医療開発センター

トップページ > グループ紹介 > 実験動物管理室(柏) > 業績

業績

2021

雑誌論文(欧文)

  1. Tsumura R, Anzai T, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Antitumor effect of humanized anti‑tissue factor antibody‑drug conjugate in a model of peritoneal disseminated pancreatic cancer. Oncol Rep, 45(1): 329-336, 2021.
  2. Shiraishi T, Ikeda K, Tsukada Y, Nishizawa Y, Sasaki T, Ito M, Kojima M, Ishii G, Tsumura R, Saijou S, Koga Y, Yasunaga M, Matsumura Y. High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer. BMC Cancer, 21(1):302, 2021.

2020

雑誌論文(欧文)

  1. Tsumura R, Koga Y, Hamada A, Kuwata T, Sasaki H, Doi T, Aikawa K, Ohashi A, Katano I, Ikarashi Y, Ito M, Ochiai A. The report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan. Cancer Sci, 111(9):3386-3394, 2020.
  2. Takashima H, Koga Y, Tsumura R, Yasunaga M, Tsuchiya M, Inoue T, Negishi E, Harada M, Yoshida S, Matsumura Y. Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects. J Control Release, 323時13分8-150, 2020.

2019

雑誌論文(欧文)

  1. Koga Y, Ochiai A. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors. Cells, 8(5):418, 2019.
  2. Tsumura Y, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma rich allograft models. Cancer Sci, 110(10):3296-3305, 2019.
  3. Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N, Kagari T, Hirotani K, Yasunaga M, Matsumura Y, Doi T. U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer. Mol Cancer Therap, 18(11):2043-2050, 2019.

雑誌論文(和文)

  1. 高島大輝、津村遼、古賀宣勝、安永正浩、原田充訓、松村保広:抗がん剤内包イムノミセルの前臨床研究. Drug Delivery System 2019;34(1):29-37.
  2. 堀田欣一、松田尚久、池松弘朗、角川康夫、今井健一郎、伊藤紗代、浦岡俊夫、古賀宣勝、斎藤豊:FIT 陽性癌 vs. FIT 陰性癌(2)大腸がん検診study の立場から. INTESTINE 2019;23(5):435-440.

著書(欧文)

  1. Koga Y, Tsumura R, Matsumura Y. Preclinical Studies of ADC Therapy for Solid Tumors. Cancer Drug Delivery Systems Based on the Tumor Microenvironment. Matsumura Y., Tarin D. (eds), Springer, Tokyo, 125-154, 2019.

著書(和文)

  1. 古賀宣勝:抗体薬剤複合体開発における非臨床研究の動向. 医薬品モダリティの特許戦略と技術開発動向、技術情報協会発刊書籍、2019:152-162.
  2. 古賀宣勝、松村保広:診断法の進歩(大腸がんを例として). がん生物学イラストレイテッド第2版、渋谷正史・湯浅保仁編、羊土社、2019:363-369.

2018

雑誌論文(欧文)

  1. Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. J Control Release, 284:49-56, 2018.

2017

雑誌論文(欧文)

  1. Yamazaki N, Koga Y, Taniguchi H, Kojima M, Kanemitsu Y, Saito N, Matsumura Y. High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget, 8(4):6970-6983, 2017.
  2. Fukuoka S, Kojima T, Koga Y, Yamauchi M, Komatsu M, Komatsuzaki R, Sasaki H, Yasunaga M, Matsumura Y, Doi T, Ohtsu A. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. Oncotarget, 8(7):11020-11029, 2017.
  3. Takashima H, Tsuji A, Saga T, Yasunaga M, Koga Y, Kuroda J, Yano S, Kuratsu J, Matsumura Y. Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Sci Rep, 7(1):12341, 2017.
  4. Koga Y. miRNAs are stable in several severe storage conditions and useful for molecular diagnostics. J Tumor Med Prev, 1(4): 555568, 2017.
  5. Yamazaki N, Koga Y, Matsumura Y. MicroRNA analysis of colorectal cancer using fecal and tissue samples. RNA Dis, 4(3):e1592, 2017.
  6. Yasunaga M, Manabe S, Tsuji A, Furuta M, Ogata K, Koga Y, Saga T, Matsumura Y. Development of antibody–drug conjugates using DDS and molecular imaging. Bioengineering, 4:78, 2017.

雑誌論文(和文)

  1. 安永正浩、眞鍋史乃、辻厚至、古田大、 緒方是嗣、古賀宣勝、藤原悠起、佐賀恒夫、松村保広:分子イメージングを駆使したADCの開発. 薬学雑誌 2017;137(5):535-544.

2016

雑誌論文(欧文)

  1. Sugaya A, Hyodo I, Koga Y, Yamamoto Y, Takashima H, Sato R, Tsumura R, Furuya F, Yasunaga M, Harada M, Tanaka R, Matsumura Y. Utility of epirubicin-incorporating micelle tagged with anti-tissue factor antibody clone with no anticoagulant effect. Cancer Sci, 107(3):335-340, 2016.
  2. Fujiwara Y, Furuta M, Manabe S, Koga Y, Yasunaga M, Matsumura Y. Imaging mass spectrometry for the precise design of antibody-drug conjugates. Sci Rep, 6時24分954, 2016.
  3. Kudo M, Yamamoto Y, Koga Y, Hamaguchi T, Akimoto T, Yasunaga M, Matsumura Y. Effect of combined treatment with micelle-incorporated cisplatin (NC-6004) and S-1 on human gastric cancer xenografts. Mol Clin Oncol, 5:817-822, 2016.  

雑誌論文(和文)

  1. 古賀宣勝:糞便中のDNA検査.検査と技術 2016; 44(4):290-292
  2. 古賀宣勝:劣悪な検体でも解析可能なmiRNAの利用法.Pharm Stage 2016; 16(7):42-47